Melphalan

Melphalan, the active ingredient in Melphalan, is an alkylating agent (nitrogen mustard) presented as a intravenous solution for intravenous use. It treats multiple myeloma, ovarian cancer, melanoma, and breast cancer in adult patients.

GNH USA supplies Melphalan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Melphalan is an alkylating antineoplastic agent used in the treatment of several solid tumours and hematologic malignancies.

Multiple myeloma: induces remission or disease control in eligible patients. Ovarian cancer: used as part of combination regimens to reduce tumour burden. Melanoma: administered in advanced disease to achieve tumour regression. Breast cancer: employed in high‑risk or metastatic settings to improve response rates.

Melphalan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during infusion. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Alopecia: hair loss occurring during treatment cycles. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers after prolonged exposure. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases.

Prior to initiating therapy, clinicians should assess baseline health status and monitor for potential complications. - Blood count monitoring: perform regular CBC to detect myelosuppression. - Renal function assessment: evaluate creatinine clearance before each cycle. - Pregnancy avoidance: drug is contraindicated in pregnancy (Category D). - Infection vigilance: postpone treatment in the presence of active severe infection. - Storage at controlled room temperature: keep in original container, protect from light and moisture.

Melphalan can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent alkylating agents: additive bone‑marrow suppression. - High‑dose radiation therapy: increased risk of tissue injury. - Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance myelosuppressive effects. - Anticoagulants: increased bleeding tendency. - Diuretics: potential impact on renal clearance of melphalan.